European Orphan Designation granted for PBT434 for MSA
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- AGM Presentation 2019
- Chairmans Address to Shareholders
- Lead drug candidate receives positive opinion from EMA
- Appendix 4E & Annual Report 2019
- Successful Completion of Phase 1 Clinical Trial
Later from Alterity Therapeutics
- Alterity receives a $4.8 million R&D Tax Incentive Refund
- Appendix 4C - quarterly
- NASDAQ Non-Compliance Notice Received
- NASDAQ Temporary Relief
- Appendix 4C and Quarterly Update
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics